Neurology & Psychiatry · LP-160
Haloperidol Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-160Neurology & Psychiatry
- Generic identity
- HaloperidolTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-160
- Generic ingredient
- Haloperidol
- Dosage form
- Tablet
- Proposed strength
- 1.5 mg; 5 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Neurology & Psychiatry
About Haloperidol
Haloperidol is a conventional antipsychotic that mainly affects dopamine signalling. Oral tablets are used in selected psychiatric or neurological contexts after professional assessment. The benefit-risk profile depends on diagnosis, patient vulnerability and concurrent medicines. Haloperidol tablets, short-acting injection and depot injection are distinct presentations, so this entry must not be used as a route-conversion or substitution guide.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
A clinical plan should define the target symptoms and review mental state, physical health and movement-related adverse effects. A medical cause of agitation or behavioural change needs evaluation rather than automatic antipsychotic treatment. Use in older adults with dementia has important safety limitations. The cited information is general education about haloperidol and should not be read as confirming every external-label indication for a Luang Pharma tablet.
Important safety considerations
Abnormal movements, akathisia, parkinsonism, sedation and postural symptoms can occur. Tardive dyskinesia, neuroleptic malignant syndrome and dangerous cardiac rhythm disturbances are serious risks. Antipsychotic treatment increases mortality risk in older adults with dementia-related psychosis. Parkinson disease, cardiac disease, electrolyte abnormalities and medicines that prolong the QT interval require particular review. Fever with rigidity, collapse or a new arrhythmia demands urgent medical assessment.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source lists oral tablets in two strengths. Immediate versus other formulation characteristics, scoring and excipients require confirmation. Tablet strength must not be confused with injection concentration, and oral and parenteral orders require distinct product records.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the diagnosis, cardiac and movement-risk assessment, electrolyte status where relevant, interacting medicines and monitoring plan. Review age- and condition-specific restrictions in the authorized label.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Haloperidol
- Dosage form / presentation
- Tablet
- Catalogue strength
- 1.5 mg; 5 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- This is an oral tablet record. Exact chemical form, tablet properties, scoring and excipients require controlled product documentation and must not be inferred from injectable haloperidol references.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Haloperidolgovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-160, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-160.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.